

**Prediction of individual life-years gained without cardiovascular events from lipid, blood pressure, glucose, and aspirin treatment based on data of more than 500,000 patients with type 2 diabetes mellitus**

G.F.N. Berkelmans, MD<sup>1</sup>; S. Gudbjörnsdottir, MD, PhD<sup>2</sup>; F.L.J. Visseren, MD, PhD<sup>1</sup>; S.H. Wild, MB BChir, PhD<sup>3</sup>; S. Franzen, PhD<sup>2</sup>; J. Chalmers, MD PhD<sup>4</sup>; B.R. Davis, MD PhD<sup>5</sup>; N.R. Poulter, F Med Sci<sup>6</sup>; A.M. Spijkerman, PhD<sup>7</sup>; M. Woodward, MD PhD<sup>4,8</sup>; S.L. Pressel, MS<sup>5</sup>; A.K. Gupta, MD PhD<sup>6,9</sup>; Y.T. van der Schouw, PhD<sup>10</sup>; A.M. Svensson, PhD<sup>2</sup>; Y. van der Graaf, MD PhD<sup>10</sup>; S.H. Read, PhD<sup>3</sup>; B. Eliasson, MD, PhD<sup>2</sup>; J.A.N. Dorresteyn, MD, PhD<sup>1</sup>

<sup>1</sup>Department of Vascular Medicine, University Medical Center Utrecht, the Netherlands.

<sup>2</sup>Swedish National Diabetes Register, Center of Registers in Region, Gothenburg, Sweden.

<sup>3</sup> Usher Institute of Population Health Sciences and Informatics, University of Edinburgh, Edinburgh, Scotland, UK. and on behalf of the Scottish Diabetes Research Network epidemiology group

<sup>4</sup>The George Institute for Global Health, University of New South Wales, Sydney, Australia.

<sup>5</sup>Department of Biostatistics, University of Texas School of Public Health, Houston, TX, USA.

<sup>6</sup>ICCH, Imperial College London, London, United Kingdom.

<sup>7</sup>National Institute for Public Health and the Environment (RIVM), Bilthoven, The Netherlands.

<sup>8</sup>Department of Epidemiology, Johns Hopkins University, Baltimore, USA; The George Institute for Global Health, University of Oxford, UK.

<sup>9</sup>William Harvey Research Institute, Queen Mary University of London, London, UK.

<sup>10</sup>Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, the Netherlands.

**Corresponding author**

F.L.J. Visseren, MD, PhD

Department of Vascular Medicine, University Medical Centre Utrecht

PO Box 85500, 3508 GA Utrecht, The Netherlands

Phone: +31 (0)88 7555161; Fax: +31 (0)30 2523741

Email: [f.l.j.visseren@umcutrecht.nl](mailto:f.l.j.visseren@umcutrecht.nl)

Word count: 4391(excl. abstract, disclosure, acknowledgements, references, supplementary appendix).

Word count abstract: 249

Number of tables and figures: 2 tables, 2 figures (excluding supplementary appendix)

## **Abstract**

**Aim:** Although group-level effectiveness of lipid, blood pressure, glucose, and aspirin treatment for prevention of cardiovascular disease (CVD) has been proven by trials, important differences in absolute effectiveness exist between individuals. We aim to develop and validate a prediction tool for individualizing lifelong CVD prevention in people with T2DM predicting life-years gained without myocardial infarction or stroke.

**Methods and results:** We developed and validated the Diabetes Lifetime-perspective prediction (DIAL)-model, consisting of two complementary competing risk adjusted Cox proportional hazards functions using data from people with T2DM registered in the Swedish National Diabetes Registry (n=389,366). Competing outcomes were: 1) CVD-events (vascular mortality, myocardial infarction or stroke), 2) non-vascular mortality. Predictors were age, sex, smoking, systolic blood pressure, BMI, HbA1c, eGFR, Non-HDLc, albuminuria, T2DM duration, insulin treatment, history of CVD. External validation was performed using data from the ADVANCE, ACCORD, ASCOT and ALLHAT-LLT-trials, the SMART and EPIC-NL-cohorts, and the Scottish diabetes register (total n=197,785). Predicted and observed CVD-free survival showed good agreement in all validation sets. C-statistics for prediction of CVD were 0.83 (95% CI 0.83-0.84) and 0.64 to 0.65 for internal and external validation respectively. We provide an interactive calculator at [www.U-Prevent.com](http://www.U-Prevent.com) that combines model predictions with relative treatment effects from trials to predict individual benefit from preventive treatment.

**Conclusions:** CVD-free life expectancy and effects of lifelong prevention in terms of CVD-free life years gained can be estimated for people with T2DM using readily available clinical characteristics. Predictions of individual-level treatment effects facilitate translation of trial results to individual patients.

**Keywords:** Cardiovascular; Type 2 diabetes mellitus; Lifetime prediction; Lifelong prevention.

## Introduction

People with T2DM are at up to 2-fold increased risk for cardiovascular disease (CVD) compared to people without T2DM independently from other risk factors.<sup>1</sup> Estimated reductions in life expectancy and quality adjusted life years (QALYs) due to CVD are substantial in people with T2DM especially in people diagnosed with T2DM at young ages.<sup>2,3</sup> International guidelines on CVD prevention recommend lipid-lowering, blood pressure-lowering, and glucose-lowering treatment to achieve the respective targets and for some patients also aspirin use.<sup>4,6</sup> More recently, new drugs have become available to further reduce the burden of CVD in patients with T2DM. These include PCSK9-inhibition, SGLT2-inhibition and GLP1-analogues.<sup>7,8</sup> Guideline recommendations on the use of these preventive medications are based on the group-level effectiveness of such medication as shown in high-quality trials. Yet, important differences in absolute effectiveness are known to exist between individuals. Clinicians may struggle to identify individuals that benefit most from intensive and newer treatment options as the translation of group-level findings and recommendations to the individual patient level is extremely challenging. As individual effectiveness of preventive treatment is mainly determined by individual baseline CVD-risk, risk estimation could help to individualize treatment.<sup>9</sup> In general, people with higher individual cardiovascular risk will benefit more in absolute terms from lipid-lowering, glucose-lowering, or blood pressure lowering than people with a lower cardiovascular risk.

Therefore, the use of CVD risk prediction models for people with T2DM, such as the UKPDS, ADVANCE, Fremantle, and New Zealand Diabetes risk scores have been recommended in various national guidelines.<sup>10-13</sup> Yet, most existing prediction models predict five-year risks of CVD.<sup>14</sup> Medications for prevention of CVD, on the other hand, are usually continued life-long and for most patients this means much longer than five years. Therefore, estimates of long-term CVD-risk and CVD-free life expectancy (i.e. expected number of remaining life-years without the occurrence of an incident or recurrent myocardial infarction or stroke) are usually more informative.<sup>15,16</sup> Several lifetime-perspective models are already available for healthy individuals, but not for patients with T2DM.<sup>17,18</sup>

The objective of the present study is to develop and externally validate a prediction tool (i.e. the Diabetes Lifetime-perspective prediction (DIAL)-model), for individualizing lifelong CVD prevention with lipid-lowering, anti-hypertensive, glucose-lowering, and aspirin treatment in people with T2DM by predicting treatment effects as gains in 10-year CVD-risk, lifetime risk, and CVD-free life expectancy. Notably, CVD-free life expectancy for a person with a history of CVD should be interpreted as time without recurrent myocardial infarction or stroke.

## **Methods**

### *Sources of data*

The Swedish National Diabetes Registry (NDR) and the Scottish Care Information (SCI) –Diabetes database are population wide registers. The secondary Manifestation of ARterial disease (SMART) study and European Prospective Investigation into Cancer-Netherlands (EPIC-NL) are prospective cohort studies and Action to Control Cardiovascular Risk in Diabetes (ACCORD), the Action in Diabetes and Vascular disease: preterAx and diamicroN-MR Controlled Evaluation (ADVANCE), Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT) and the Lipid Lowering Trial component of the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT) are randomised controlled trials, all including people with T2DM. Study details have been described elsewhere.<sup>19-27</sup> The lifetime-perspective prediction model was developed in the Swedish NDR and externally validated in the remaining datasets. All use of data from registries, cohorts and trials were approved by institutional review boards and all participants gave written informed consent before taking part in the cohorts and trials. All studies complied with the Declaration of Helsinki.

### *Participants*

Participants were people aged >18 years with a diagnosis of T2DM with or without prevalent CVD. People with a previous diagnosis of cancer (ICD-10 codes C00-C97) or stage 4 or 5 chronic kidney disease (estimated glomerular filtration rate, eGFR <30 mL/min) were excluded. A comprehensive

overview of the eligibility criteria and definition of T2DM used for the original cohorts and trials are provided in table S1.

### *Outcomes*

CVD was defined as a non-fatal myocardial infarction, non-fatal stroke, or vascular mortality. In the Swedish NDR and the SCI –Diabetes database, this is based on linkage to cause of death registers and hospital discharge registers using ICD-10 codes. All endpoint definitions of all studies are described in table S1. Non-vascular mortality was defined as all deaths other than those with an identified cardiovascular cause as described in table S1.

### *Predictors*

Based on existing diabetes risk scores and availability in routine clinical practice, eleven selected predictors were: sex (female/male), current smoking (yes/no), systolic blood pressure (SBP in mmHg), body-mass index (BMI in kg/m<sup>2</sup>), haemoglobin A1c (HbA1c) measured using the International Federation of Clinical Chemists (IFCC) reference method (in mmol/mol), eGFR estimated by the Chronic Kidney Disease Epidemiology Collaboration equation<sup>28</sup> (CKD-EPI in ml/min/1.73m<sup>2</sup>), non-high-density lipoprotein cholesterol (non-HDLc in mmol/l), albuminuria (no/micro/macro), duration of T2DM (years since diagnosis), insulin treatment (yes/no), history of CVD (yes/no).<sup>10-13, 29</sup> The number, proportion, and type of missing data, and methods dealing with missing data in each dataset are described in the supplementary appendix. No multicollinearity was detected between predictors.

### *Statistical analysis*

#### *Development of the lifetime model*

A random sample of 75% of people from the Swedish NDR (n=292,024) was used as the development dataset. Continuous predictors were truncated at the 1st and 99th percentile to limit the effect of outliers. Using these data, we developed two complementary Fine and Gray competing risk adjusted Cox

proportional hazard models with left truncation and right censoring: one for the prediction of CVD events using non-vascular mortality as the competing endpoint (i.e. model part A), and another for the prediction of non-vascular mortality using CVD events as the competing endpoint (i.e. model part B). Cumulative CVD-free survival was calculated using the complementary models making use of life-tables with one-year time intervals. CVD-free life expectancy of an individual was defined as the median survival without myocardial infarction or stroke or death, which was the age where the estimated cumulative survival drops below 50%. 10-year CVD-risk was calculated by summation of the predicted cause-specific CVD risk in the first 10 years from a person's current age onwards. Similarly, lifetime risk was calculated by the summation of the predicted cause-specific CVD risk from a person's current age onwards until the maximum age of 95.<sup>15, 30</sup> A description of the statistical methods is described in the supplementary appendix. The sample size was more than sufficient by conventional assessment for prediction models with >1000 endpoints per variable.<sup>31</sup>

#### *Model validation*

Goodness of fit was assessed for vascular events, non-vascular mortality and the combined outcome of CVD-free survival separately using calibration plots for internal and external validation (supplementary appendix).<sup>32</sup> The models were recalibrated based on the incidence of CVD and incidence of non-vascular mortality using the expected versus observed ratio in data from all geographic regions. The logarithm of the expected versus observed ratio was subtracted from the linear predictor. Discrimination was quantified using c-statistics.

#### *Prediction of individual treatment effect*

We combined competing risk adjusted Cox proportional hazard function A for prediction of CVD with hazard ratios from randomised trials or meta-analyses to predict the individual treatment effect and lifetime benefit of treatment. The hazard ratio of smoking cessation on non-vascular mortality was added to competing risk adjusted Cox proportional hazard function B when predicting the effect of smoking

cessation. All other predicted treatment effects were assumed to have no effect on non-vascular mortality (i.e. lipid, blood pressure, glucose, and aspirin treatment). This method of calculating projected individual treatment effects has previously been applied by the American Heart Association and American College of Cardiology in their 'ASCVD risk estimator plus' based on the Pooled Cohort Equations for primary prevention.<sup>18</sup> By using life-tables, any gains in CVD-free survival is automatically adjusted for competing risks by increasing the time at risk for non-CVD mortality. In this study, we derived estimates of the effect of lipid-lowering, glucose-lowering, blood pressure-lowering, and aspirin treatment.<sup>8, 33, 34</sup> The hazard ratios for different medications used (statins, ezetimibe, PCSK9-inhibitors, antihypertensive medication, HbA1c-lowering, SGLT2-inhibitors, GLP1analogues, and aspirin) to estimate treatment effects are described in the supplementary appendix. We also derived estimates of the effect of smoking cessation. Smoking cessation was unlike drug therapy assumed to have an effect on both CVD and non-vascular mortality (i.e. cancer mortality).<sup>35, 36</sup>

The lifetime benefit of treatment for an individual person was calculated as the difference between the predicted median CVD-free life expectancy with and without treatment. Similarly, lifetime and 10-year absolute CVD-risk reduction for individual persons were estimated by calculating the difference between the predicted 10-year CVD-risk with and without treatment. 95% CI were calculated for the estimates, representing uncertainty of the model development and relative effects of trial results. This was performed using bootstrap techniques. However, due to computational issues, bags of little bootstraps were necessary. First, 100 random samples without replacement of  $n^{0.8} = 292,024^{0.8} = 23,569$  patient were computed. In each random sample, 400 bootstrap samples were taken to obtain boundaries of 95% CIs. The average of all 100 upper and lower 95% CI gave the 95% confidence interval around the predicted estimates.<sup>37</sup>

## Results

The selection of development and validation cohorts from the Swedish NDR is illustrated in figure S1. Baseline characteristics of all study populations are described pooled by geographical origin in table 1, and stratified by original study cohort in table S4.

### *Development of the DIAL model*

The calculation formulae including the coefficients of the Cox proportional hazard functions, age-specific baseline survivals, and HRs of intended treatment of the model are provided in table S5 and S6. The hazard ratios (HRs) for Cox proportional hazard functions A and B of the DIAL model are shown in table 2. Quadratic transformation of continuous predictors was applied for BMI, SBP, HbA1c, non-HDL-c, and eGFR for Cox proportional hazard function A (CVD) and for BMI, SBP, and BMI for Cox proportional hazard function B (non-vascular mortality). Interactions between age and sex, smoking, history of CVD, and treatment with insulin, were added to Cox proportional hazard function A and B. Due to the presence of competing risks, interactions with age and transformations of determinants the coefficients and hazard ratios as presented in table 2 should be interpreted with caution. For example, although the HR of history of CVD in model part B (non-vascular mortality) is 0.25, this should not be interpreted as a protective effect from an etiological perspective. More likely, from a prognostic perspective, increased incidence of vascular events in patients with a history of CVD simply results in a less frequent observation of non-vascular mortality. Also, since history of CVD interacts with age, the HRs are presented for a 65 year old patients and change with changing age. Furthermore, HRs need to be seen in combination with the age specific baseline hazards and are therefore difficult to interpret.

### *Internal validation*

Predicted 10-year risk for CVD and all-cause mortality (CVD risk and non-vascular mortality risk combined) showed good agreement with the 10-year observed risk in the development dataset (figure S2).



The c-statistics were 0.83 (95% CI 0.83 to 0.84), 0.72 (0.72-0.73) and 0.77 (0.76-0.77) for 10-year CVD-risk, 10-year non-vascular mortality risk, and 10-year CVD-free survival respectively.

### *External validation*

Predicted 5-year risk for CVD and all-cause mortality showed good agreement with the observed 5-year CVD-free survival in Western-Europe, Eastern-Europe, North-America and Asia and Oceania (figure 1). The c-statistic of the estimated 5-year CVD-risk was between 0.64 and 0.65 in all geographically pooled datasets. C-statistics for 5-year non-vascular mortality risk (range 0.59-0.67) and 5-year risk for CVD and all-cause mortality (range 0.64-0.69) are shown in table S7. CVD event rates were higher in the Scottish Care Information –Diabetes database (17 per 1000 people per year) compared to the Swedish NDR (11 per 1000 people per year). After recalibrating the model for differences in predicted versus observed event rates, external validation in Scottish data showed good agreement between the predicted and observed 10-year risk for CVD and all-cause mortality (figure 1). Discrimination of 10-year CVD-risk was 0.64 (95% CI 0.64 to 0.65; table S7).

### *Individual lifetime estimates and treatment effects for people with T2DM*

An interactive calculator is provided at [www.U-Prevent.com](http://www.U-Prevent.com). Patient characteristics and current medication can be entered in this decision support tool to estimate individual risk and CVD-free survival. Also the individual effect from medication changes can be modelled in terms of CVD-free life years gained, absolute risk reduction and individual number needed to treat. Absolute treatment effects vary widely between individuals. As an example, we modelled that a combination therapy of simvastatin 40mg, ezetimibe 10mg and systolic blood pressure-lowering to 140mmHg, conferred between 0.04 (95% CI 0.01 - 0.04) and 12.5 (95% CI 11.0 - 21.2) years gained without CVD-events in people enrolled in the Swedish NDR. Treatment effect was lowest (<0.05 CVD-free years) in people who were 78 years or older, without a history of vascular disease, systolic blood pressure of <140mmHg, and LDL-c of <3.0 mmol/L at baseline. Treatment effect was highest (>10 CVD-free years) in people aged 55 to 70, with a

history of vascular disease, systolic blood pressure >160 mmHg and LDL-c >3.0 mmol/L at baseline. As another illustration example, figure 2 shows the expected result of starting the same treatment (i.e. simvastatin 40 mg) in three different people with T2DM.

## Discussion

In this study we have developed and validated the DIAL model to predict CVD-free life expectancy, lifetime risk and 10-year CVD risk in people with T2DM using widely available patient characteristics. The novelty of this tool compared to previous models is that it not only predicts 5 or 10-year risk, but also long-term perspective outcomes. In addition the DIAL-model takes competing non-cardiovascular mortality into account and can, therefore, be used to estimate unbiased lifetime benefits of preventive treatment when combined with trial-findings. Therefore, the DIAL model may help clinicians to translate group-level trial findings to the individual patient. The interactive calculator at [www.U-Prevent.com](http://www.U-Prevent.com) facilitates the actual use of the DIAL-model in clinical practice. We have validated the DIAL model in populations from different continents and have demonstrated that, after re-calibration, it has the potential to support medical decision-making for CVD prevention in people with T2DM in diverse populations. The discriminative ability of the model was moderate in each external validation dataset consistent with external validation of previous risk scores. For example validation of the ADVANCE risk score in EPIC-NL and SMART gave C-statistics of 0.62 and 0.68 respectively.<sup>38</sup> The cardiovascular event rate was higher in Scotland compared to Sweden, due to differences in multiple factors not taken into consideration in the model, including lifestyle differences. Recalibration of the DIAL model allows it to be adapted for use in populations with varying levels of CVD risk. Users can choose to apply either the low-risk CVD event rate (based on the Swedish cohort, i.e. 11/1000 people per year) or the high-risk event rate (based on the Scottish cohort, i.e. 17/1000 people per year), whichever is more appropriate for their population. Although calibration plots show an overestimation for patients at the highest risk, in clinical practice this is unlikely to lead to erroneous clinical decisions. Overestimation occurs in patients with 5-year risks of >20% (corresponding to 10-year risks of >40%). Even though overestimated, the true

observed risk in these patients is still very high and should urge for intensive medical therapy anyway.

Also, overestimation of risk in the high-risk patient category is not a specific limitation of the DIAL-model, but in line with previous validation studies of CVD-risk models in diabetes patients.<sup>38</sup>

Several studies have convincingly demonstrated the advantage of lifetime prediction compared to traditional 5-year or 10-year risk predictions. A microsimulation model based on 5-year follow-up of the Rotterdam Study showed that the gain in total CVD-free life expectancy increased as risk factor levels increased. The gain in total CVD-free expectancy decreased with advancing age, whereas 10-year risk for CVD mortality, and therefore 10-year risk reduction, increased with age.<sup>39</sup> In other primary prevention settings for example, smoking cessation at age 60, 50, 40, or 30 years resulted in about 3, 6, 9, and 10 years of life years gained respectively. This indicates that the highest lifetime benefit can be gained by reducing risk factors early in life, ideally with lifestyle interventions but, if necessary, with drug treatment.<sup>40</sup>

In clinical practice, prediction of lifetime benefit in CVD-free life years gained would enable patients (as well as clinicians) to better understand the potential benefits of treatment. Such information could help patients to participate in the decision-making process about treatment and may also motivate them to adhere to therapy. Clinicians and patients can balance the benefit and possible disadvantages of treatment, to decide whether preventive medication should be started or stopped. Also, the ability to estimate which preventive therapy is most effective (e.g. lipid-lowering, glucose-lowering, blood pressure-lowering, or aspirin treatment) can help to decide what treatment should be initiated first, and what treatment can be postponed or not prescribed to avoid excessive polypharmacy.

Using the concept of predicting lifetime benefit for making treatment decisions will result in changing characteristics of people eligible for treatment, towards higher proportions of younger people with higher risk factor levels. This group of people need to be treated over a longer period of time resulting in higher treatment costs. Prediction based treatment using the DIAL-model could theoretically also lead to higher cost-effectiveness of treatment on a group level. This, of course, should be confirmed by future cost-effectiveness studies. Also, it is not clear whether stopping treatment in older people would offset these

costs and health economic analyses are required to investigate and to establish appropriate thresholds of minimum gain in life-years free of CVD.

The strengths of this study include the use of a large number of people from diverse cohorts. Since the Swedish and SCI –Diabetes database are registries with information for over 90% of people with T2DM in both countries, there is limited selection of people with T2DM, in contrast to trial populations.<sup>41</sup>

Therefore, these registries are close to true representations of their populations and this increases the generalisability of the DIAL-model to clinical practice. Extensive validation of the DIAL model in large and diverse populations supports the use of the DIAL-model in people with T2DM without chronic kidney disease (eGFR <30) or metastatic cancer in different parts of the world. However, new external validation studies using data of other and new trials including T2DM patients could further enhance the validity of the DIAL-model.

Some limitations of the DIAL model should be considered. Although our model can guide the decision to start treatment for the prevention of CVD, it must be emphasised that there are other reasons for people with T2DM to start preventive therapy (e.g. prevention of neuropathy, retinopathy, diabetic nephropathy, or foot ulcers). The DIAL-model predictions do not incorporate these effects and may, therefore, underestimate the total treatment benefits. In addition, some people use preventive medication for other indications. For example, lipid lowering drugs are also used for monogenetic dyslipidaemias, antihypertensive drugs are used to reduce progression of aneurysms, and diuretics are used for heart failure. The DIAL-score may not be applicable to people with such co-morbidities. Additional risk factors such as socio-economic status, coronary calcium scores and ethnicity have not been incorporated in the model and may have improved performance. However, addition of more risk factors to prediction models generally only leads to minor improvements model performance.<sup>42</sup> Finally, the initial and most effective approaches to primary and secondary prevention of T2DM are lifestyle changes, such as sufficient physical activity, healthy diet and, where appropriate, weight loss. Clearly prediction of effects of lifestyle interventions would be valuable. However, it is currently not feasible to include lifestyle factors in

prediction models given the lack of robust estimates of the effect size for lifestyle interventions from randomised controlled trials.

Other limitations of the methods used to develop and validate the DIAL model, and to estimate treatment effects should be acknowledged. Validation could only be performed for 10-year and 5-year predictions due to the limited follow-up in the included cohorts and trials. Lifetime estimates often go beyond 10-year predictions, and require the assumption that rates will be similar for a current 40 year old in 40 years' time to those of an 80 year old today. This is a major assumption but previous studies have shown that lifetime estimates based on the methods we used appear to apply for a survival of up to 17 years.<sup>15</sup> Nevertheless, longer-term validation would be preferable and will be possible as follow up data accrue in Sweden and Scotland. Also, the lifetime benefits are calculated assuming immediate, lifelong, successful (i.e. targets reached) and uninterrupted treatment from their current age onwards. The estimated treatment effects are the maximum potential benefit with treatment (i.e. full adherence, usage as prescribed). In clinical practice treatment adherence to preventive medication is reported to be 50% primary and 66% in secondary cardiovascular prevention settings.<sup>43</sup> Yet the DIAL-model is intended to support medical decision-making by providing estimates about what a patient and health care professional can expect when adhering to a treatment as prescribed. The predicted treatment effects are based on the results of large randomized clinical trials in which adherence to treatment usually is about 80%. Furthermore, possible changes in risk factor levels over time were not taken into account. For example, blood pressure and cholesterol were assumed to remain stable over time. Therefore, re-evaluation of CVD-free survival and treatment effects after 5 to 10 years is advised based on our validation to ensure valid predictions to guide treatment decisions.

In conclusion, CVD-free life expectancy as well as the effect of lifelong lipid-lowering, glucose-lowering, blood pressure-lowering, and aspirin treatment in terms of CVD-free life years gained can be reliably predicted for people with T2DM using readily available characteristics. The DIAL model may facilitate personalized treatment and support shared decision-making and patients' motivation to adhere to prescribed drug-treatments to reduce CVD risk.

## **Acknowledgements**

For the Swedish national diabetes registry, we thank all of the clinicians who were involved in the care of patients with diabetes for collecting data, and staff at the Swedish National Diabetes Registry. We acknowledge with gratitude the contributions of people and organisations involved in providing data, setting up, maintaining and overseeing SCI-Diabetes, including the Scottish Diabetes Research Network that is supported by National Health Service (NHS) Research Scotland, a partnership involving Scottish NHS Boards and the Chief Scientist Office of the Scottish Government.

For the SMART study, we gratefully acknowledge the contribution of the SMART research nurses, Rutger van Petersen, MSc (data manager), Baukje G.F. van Dinther, MSc (manager Utrecht Cardiovascular Cohort), and the members of the SMART study group: Ale Algra, MD, PhD; Yolanda van der Graaf, MD, PhD; Diederick E. Grobbee, MD, PhD; Guy E.H.M. Rutten, MD, PhD, Julius Center for Health Sciences and Primary Care; Frank L.J. Visseren, MD, PhD, Department of Internal Medicine; Gert J. de Borst, MD, PhD, Department of Vascular Surgery; L. Jaap Kappelle, MD, PhD, Department of Neurology; Tim Leiner, MD, PhD, Department of Radiology; Hendrik M. Nathoe, MD, PhD, Department of Cardiology.

The EPIC-Netherlands study is supported by the “Europe Against Cancer” Programme of the European Commission; Dutch Ministry of Health, Welfare and Sports; Netherlands Organisation for Health Research and Development; and World Cancer Research Fund.

The ASCOT study was supported by Pfizer, Servier Research Group (Paris, France), Leo Laboratories (Copenhagen, Denmark), and Solvay Pharmaceuticals (Brussels, Belgium).

The ALLHAT study was supported by contract NO1-HC-35130 with the National Heart, Lung, and Blood Institute and study medications were supplied by Bristol-Myers Squibb (pravastatin), and financial support was provided by Pfizer.

The Action in Diabetes and Vascular Disease: Preterax and Diamicron MR Controlled Evaluation (ADVANCE) trial was funded by grants from the National Health and Medical Research Council of Australia and Servier International.

The ACCORD study was supported by grants from the National Heart, Lung, and Blood Institute; by other components of the National Institutes of Health, including the National Institute of Diabetes and Digestive and Kidney Diseases, the National Institute on Aging, and the National Eye Institute; by the Centers for Disease Control and Prevention; and by General Clinical Research Centers.

For the present study, the above supporting sources had no involvement in study design, analysis, interpretation and writing of the results and decision to submit the report for publication.

#### **Conflicts of interest**

G.F.N. Berkelmans declares no conflict of interest.

S. Gudbjörnsdottir declares no conflict of interest.

F.L.J. Visseren declares no conflict of interest.

S.H. Wild declares no conflict of interest

S. Franzen declares no conflict of interest.

J. Chalmers declares research funding from Servier.

B.R. Davis declares no conflict of interest.

N.R. Poulter declares no conflict of interest.

A.M. Spijkerman declares no conflict of interest.

M. Woodward declares consultancy work for Amgen.

S.L. Pressel declares no conflict of interest.

A.K. Gupta declares no conflict of interest.

Y.T. van der Schouw declares no conflict of interest.

A.M. Svensson declares no conflict of interest.

Y. van der Graaf declares no conflict of interest.

S.H. Read declares no conflict of interest.

B. Eliasson declares no conflict of interest.

J.A.N. Dorresteyn declares no conflict of interest.



## References

1. Sarwar N, Gao P, Seshasai SR, Gobin R, Kaptoge S, Di Angelantonio E, Ingelsson E, Lawlor DA, Selvin E, Stampfer M, Stehouwer CD, Lewington S, Pennells L, Thompson A, Sattar N, White IR, Ray KK, Danesh J. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. *Lancet* 2010;**375**(9733):2215-22.
2. Narayan KM, Boyle JP, Thompson TJ, Sorensen SW, Williamson DF. Lifetime risk for diabetes mellitus in the United States. *Jama* 2003;**290**(14):1884-90.
3. Gu K, Cowie CC, Harris MI. Mortality in adults with and without diabetes in a national cohort of the U.S. population, 1971-1993. *Diabetes care* 1998;**21**(7):1138-45.
4. Goff DC, Jr., Lloyd-Jones DM, Bennett G, Coady S, D'Agostino RB, Gibbons R, Greenland P, Lackland DT, Levy D, O'Donnell CJ, Robinson JG, Schwartz JS, Shero ST, Smith SC, Jr., Sorlie P, Stone NJ, Wilson PW, Jordan HS, Nevo L, Wnek J, Anderson JL, Halperin JL, Albert NM, Bozkurt B, Brindis RG, Curtis LH, DeMets D, Hochman JS, Kovacs RJ, Ohman EM, Pressler SJ, Sellke FW, Shen WK, Smith SC, Jr., Tomaselli GF, American College of Cardiology/American Heart Association Task Force on Practice G. 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. *Circulation* 2014;**129**(25 Suppl 2):S49-73.
5. Perk J, De Backer G, Gohlke H, Graham I, Reiner Z, Verschuren M, Albus C, Benlian P, Boysen G, Cifkova R, Deaton C, Ebrahim S, Fisher M, Germano G, Hobbs R, Hoes A, Karadeniz S, Mezzani A, Prescott E, Ryden L, Scherer M, Syvanne M, Scholte op Reimer WJ, Vrints C, Wood D, Zamorano JL, Zannad F. European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). *European heart journal* 2012;**33**(13):1635-701.
6. Ryden L, Grant PJ, Anker SD, Berne C, Cosentino F, Danchin N, Deaton C, Escaned J, Hammes HP, Huikuri H, Marre M, Marx N, Mellbin L, Ostergren J, Patrono C, Seferovic P, Uva MS, Taskinen MR, Tendera M, Tuomilehto J, Valensi P, Zamorano JL, Achenbach S, Baumgartner H, Bax JJ, Bueno H, Dean V, Erol C, Fagard R, Ferrari R, Hasdai D, Hoes AW, Kirchhof P, Knuuti J, Kolh P, Lancellotti P, Linhart A, Nihoyannopoulos P, Piepoli MF, Ponikowski P, Sirnes PA, Tamargo JL, Torbicki A, Wijns W, Windecker S, De Backer G, Ezquerra EA, Avogaro A, Badimon L, Baranova E, Betteridge J, Ceriello A, Funck-Brentano C, Gulba DC, Kjekshus JK, Lev E, Mueller C, Neyses L, Nilsson PM, Perk J, Reiner Z, Sattar N, Schachinger V, Scheen A, Schirmer H, Stromberg A, Sudzhaeva S, Viigimaa M, Vlachopoulos C, Xuereb RG. ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the Task Force on diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and developed in collaboration with the European Association for the Study of Diabetes (EASD). *European heart journal* 2013;**34**(39):3035-87.
7. Sattar N, Preiss D, Robinson JG, Djedjos CS, Elliott M, Somaratne R, Wasserman SM, Raal FJ. Lipid-lowering efficacy of the PCSK9 inhibitor evolocumab (AMG 145) in patients with type 2 diabetes: a meta-analysis of individual patient data. *The lancet Diabetes & endocrinology* 2016;**4**(5):403-10.
8. Zheng SL, Roddick AJ, Aghar-Jaffar R, et al. Association between use of sodium-glucose cotransporter 2 inhibitors, glucagon-like peptide 1 agonists, and dipeptidyl peptidase 4 inhibitors with all-cause mortality in patients with type 2 diabetes: A systematic review and meta-analysis. *Jama* 2018;**319**(15):1580-1591.
9. Rabar S, Harker M, O'Flynn N, Wierzbicki AS, Guideline Development G. Lipid modification and cardiovascular risk assessment for the primary and secondary prevention of cardiovascular disease: summary of updated NICE guidance. *BMJ* 2014;**349**:g4356.
10. Davis WA, Knuiman MW, Davis TM. An Australian cardiovascular risk equation for type 2 diabetes: the Fremantle Diabetes Study. *Internal medicine journal* 2010;**40**(4):286-92.

11. Elley CR, Robinson E, Kenealy T, Bramley D, Drury PL. Derivation and validation of a new cardiovascular risk score for people with type 2 diabetes: the new zealand diabetes cohort study. *Diabetes care* 2010;**33**(6):1347-52.
12. Kengne AP, Patel A, Marre M, Travert F, Lievre M, Zoungas S, Chalmers J, Colagiuri S, Grobbee DE, Hamet P, Heller S, Neal B, Woodward M, Group AC. Contemporary model for cardiovascular risk prediction in people with type 2 diabetes. *Eur J Cardiovasc Prev Rehabil* 2011;**18**(3):393-8.
13. Stevens RJ, Kothari V, Adler AI, Stratton IM. The UKPDS risk engine: a model for the risk of coronary heart disease in Type II diabetes (UKPDS 56). *Clin Sci (Lond)* 2001;**101**(6):671-9.
14. van Dieren S, Beulens JW, Kengne AP, Peelen LM, Rutten GE, Woodward M, van der Schouw YT, Moons KG. Prediction models for the risk of cardiovascular disease in patients with type 2 diabetes: a systematic review. *Heart* 2012;**98**(5):360-9.
15. Dorresteijn JAN, Kaasenbrood L, Cook NR, van Kruijsdijk RCM, van der Graaf Y, Visseren FLJ, Ridker PM. How to translate clinical trial results into gain in healthy life expectancy for individual patients. *Bmj-Brit Med J* 2016;**352**.
16. Leening MJ, Berry JD, Allen NB. Lifetime Perspectives on Primary Prevention of Atherosclerotic Cardiovascular Disease. *Jama* 2016.
17. Board JBS. Joint British Societies' consensus recommendations for the prevention of cardiovascular disease (JBS3). *Heart* 2014;**100** Suppl 2:ii1-ii67.
18. Lloyd-Jones DM, Huffman MD, Karmali KN, Sanghavi DM, Wright JS, Pelser C, Gulati M, Masoudi FA, Goff DC, Jr. Estimating Longitudinal Risks and Benefits From Cardiovascular Preventive Therapies Among Medicare Patients: The Million Hearts Longitudinal ASCVD Risk Assessment Tool: A Special Report From the American Heart Association and American College of Cardiology. *Circulation* 2017;**135**(13):e793-e813.
19. Beulens JW, Monninkhof EM, Verschuren WM, van der Schouw YT, Smit J, Ocke MC, Jansen EH, van Dieren S, Grobbee DE, Peeters PH, Bueno-de-Mesquita HB. Cohort profile: the EPIC-NL study. *Int J Epidemiol* 2010;**39**(5):1170-8.
20. Committee AM. Study rationale and design of ADVANCE: action in diabetes and vascular disease--preterax and diamicon MR controlled evaluation. *Diabetologia* 2001;**44**(9):1118-20.
21. Dahlof B, Sever PS, Poulter NR, Wedel H, Beevers DG, Caulfield M, Collins R, Kjeldsen SE, Kristinsson A, McInnes GT, Mehlsen J, Nieminen M, O'Brien E, Ostergren J, Investigators A. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. *Lancet* 2005;**366**(9489):895-906.
22. Group AS, Buse JB, Bigger JT, Byington RP, Cooper LS, Cushman WC, Friedewald WT, Genuth S, Gerstein HC, Ginsberg HN, Goff DC, Jr., Grimm RH, Jr., Margolis KL, Probstfield JL, Simons-Morton DG, Sullivan MD. Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial: design and methods. *The American journal of cardiology* 2007;**99**(12A):21i-33i.
23. Gudbjornsdottir S, Cederholm J, Nilsson PM, Eliasson B, Steering Committee of the Swedish National Diabetes R. The National Diabetes Register in Sweden: an implementation of the St. Vincent Declaration for Quality Improvement in Diabetes Care. *Diabetes care* 2003;**26**(4):1270-6.
24. Officers A, Coordinators for the ACRGTA, Lipid-Lowering Treatment to Prevent Heart Attack T. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). *Jama* 2002;**288**(23):2981-97.
25. Patel A, Group AC, MacMahon S, Chalmers J, Neal B, Woodward M, Billot L, Harrap S, Poulter N, Marre M, Cooper M, Glasziou P, Grobbee DE, Hamet P, Heller S, Liu LS, Mancia G, Mogensen CE, Pan CY, Rodgers A, Williams B. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. *Lancet* 2007;**370**(9590):829-40.

26. Simons PC, Algra A, van de Laak MF, Grobbee DE, van der Graaf Y. Second manifestations of ARTERial disease (SMART) study: rationale and design. *European journal of epidemiology* 1999;**15**(9):773-81.
27. Action to Control Cardiovascular Risk in Diabetes Study G, Gerstein HC, Miller ME, Byington RP, Goff DC, Jr., Bigger JT, Buse JB, Cushman WC, Genuth S, Ismail-Beigi F, Grimm RH, Jr., Probstfield JL, Simons-Morton DG, Friedewald WT. Effects of intensive glucose lowering in type 2 diabetes. *The New England journal of medicine* 2008;**358**(24):2545-59.
28. Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF, 3rd, Feldman HI, Kusek JW, Eggers P, Van Lente F, Greene T, Coresh J, Ckd EPI. A new equation to estimate glomerular filtration rate. *Annals of internal medicine* 2009;**150**(9):604-12.
29. Cederholm J, Eeg-Olofsson K, Eliasson B, Zethelius B, Nilsson PM, Gudbjornsdottir S. Risk prediction of cardiovascular disease in type 2 diabetes: a risk equation from the Swedish National Diabetes Register. *Diabetes care* 2008;**31**(10):2038-43.
30. Geskus RB. Cause-specific cumulative incidence estimation and the fine and gray model under both left truncation and right censoring. *Biometrics* 2011;**67**(1):39-49.
31. Austin PC, Allignol A, Fine JP. The number of primary events per variable affects estimation of the subdistribution hazard competing risks model. *J Clin Epidemiol* 2017;**83**:75-84.
32. Steyerberg EW, Vickers AJ, Cook NR, Gerds T, Gonen M, Obuchowski N, Pencina MJ, Kattan MW. Assessing the performance of prediction models: a framework for traditional and novel measures. *Epidemiology* 2010;**21**(1):128-38.
33. Cholesterol Treatment Trialists C, Kearney PM, Blackwell L, Collins R, Keech A, Simes J, Peto R, Armitage J, Baigent C. Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis. *Lancet* 2008;**371**(9607):117-25.
34. Thomopoulos C, Parati G, Zanchetti A. Effects of blood-pressure-lowering treatment on outcome incidence in hypertension: 10 - Should blood pressure management differ in hypertensive patients with and without diabetes mellitus? Overview and meta-analyses of randomized trials. *Journal of hypertension* 2017;**35**(5):922-944.
35. Gellert C, Schottker B, Brenner H. Smoking and all-cause mortality in older people: systematic review and meta-analysis. *Arch Intern Med* 2012;**172**(11):837-44.
36. Mons U, Muezzinler A, Gellert C, Schottker B, Abnet CC, Bobak M, de Groot L, Freedman ND, Jansen E, Kee F, Kromhout D, Kuulasmaa K, Laatikainen T, O'Doherty MG, Bueno-de-Mesquita B, Orfanos P, Peters A, van der Schouw YT, Wilsgaard T, Wolk A, Trichopoulou A, Boffetta P, Brenner H, Consortium C. Impact of smoking and smoking cessation on cardiovascular events and mortality among older adults: meta-analysis of individual participant data from prospective cohort studies of the CHANCES consortium. *BMJ* 2015;**350**:h1551.
37. Kleiner A, Talwalkar A, Sarkar P, Jordan MI. A scalable bootstrap for massive data. *J R Stat Soc B* 2014;**76**(4):795-816.
38. van der Leeuw J, van Dieren S, Beulens JW, Boeing H, Spijkerman AM, van der Graaf Y, van der AD, Nothlings U, Visseren FL, Rutten GE, Moons KG, van der Schouw YT, Peelen LM. The validation of cardiovascular risk scores for patients with type 2 diabetes mellitus. *Heart* 2015;**101**(3):222-9.
39. Ferket BS, van Kempen BJ, Heeringa J, Spronk S, Fleischmann KE, Nijhuis RL, Hofman A, Steyerberg EW, Hunink MG. Personalized prediction of lifetime benefits with statin therapy for asymptomatic individuals: a modeling study. *PLoS Med* 2012;**9**(12):e1001361.
40. Doll R, Peto R, Boreham J, Sutherland I. Mortality in relation to smoking: 50 years' observations on male British doctors. *BMJ* 2004;**328**(7455):1519.
41. Saunders C, Byrne CD, Guthrie B, Lindsay RS, McKnight JA, Philip S, Sattar N, Walker JJ, Wild SH, Scottish Diabetes Research Network Epidemiology G. External validity of randomized controlled trials of glycaemic control and vascular disease: how representative are participants? *Diabetic medicine : a journal of the British Diabetic Association* 2013;**30**(3):300-8.

42. Austin PC, Pencinca MJ, Steyerberg EW. Predictive accuracy of novel risk factors and markers: A simulation study of the sensitivity of different performance measures for the Cox proportional hazards regression model. *Stat Methods Med Res* 2017;**26**(3):1053-1077.
43. Naderi SH, Bestwick JP, Wald DS. Adherence to drugs that prevent cardiovascular disease: meta-analysis on 376,162 patients. *The American journal of medicine* 2012;**125**(9):882-7 e1.

## Legends

**Figure 1:** Calibration plots in external dataset pooled by geographical region.

Predicted versus observed 5-year risk of CVD and all-cause mortality according to the DIAL-model in quintiles of risk in A) Eastern-Europe, B) Western-Europe, C) North-America, and D) Asia and Oceania. E) Predicted versus observed 10-year risk of CVD and all-cause mortality according to the DIAL-model in deciles of risk in Scotland.

**Figure 2:** Examples of treatment effects of simvastatin 40 mg versus no treatment in people with different characteristics.

	Patient A	Patient B	Patient C
Age (years)	55	65	80
Sex	male	female	female
Smoking status	no	no	no
Duration of T2DM (y)	5	5	10
Insulin therapy	no	no	no
Systolic blood pressure (mmHg)	150	145	140
Body-mass index (kg/m <sup>2</sup> )	27	27	30
HbA1c (mmol/mol)	55	55	55
Non-HDL-c (mmol/l)	5	6	5
eGFR (ml/min/1.73m <sup>2</sup> )	70	70	60
Albuminuria	no	no	micro-albuminuria
History of CVD	yes	no	yes
LDL-c (mmol/l)	3.0	4.5	3.0
10 year-risk (%)	27.1 (20.1 - 31.5)	3.7 (2.7 - 4.6)	46.4 (37.9 - 53.4)
10-year ARR (%)	5.8 (4.4 - 6.7)	1.2 (0.9 - 1.6)	8.4 (7.0 - 9.4)
10-year NNT	17 (15 - 23)	83 (64 - 115)	12 (11 - 14)
CVD-free survival (y)	71.5 (70.0 - 73.9)	85.2 (84.2 - 86.6)	86.6 (85.6 - 87.7)
Lifetime gain free of CVD (y)	2.9 (2.3 - 3.4)	0.4 (0.3 - 0.6)	1.3 (0.9 - 1.5)
Lifetime CVD risk (% until 95 years)	82.9 (74.7 - 86.1)	6.3 (5.1 - 8.8)	53.0 (43.6 - 60.4)

**Table 1.** Baseline characteristics for study populations used in the DIAL model pooled by geographical origin.

	Derivation	Validation					
	NDR derivation	NDR validation	Western-Europe	Eastern-Europe	North-America	Asia and Oceania	Scotland
Group size	(n = 292,024)	(n = 97,342)	(n = 7,742)	(n = 2,142)	(n = 14,590)	(n = 5,580)	(n = 167,731)
Age (y)	65 (57-74)	65 (57-74)	65 (59-70)	65 (59-71)	63 (58-68)	65 (60-69)	60 (51-68)
Sex (Male)	164,672 (56%)	54,584 (56%)	5,074 (66%)	949 (44%)	8,488 (58%)	3,196 (57%)	96,989 (58%)
Current smoking	48,235 (17%)	16,206 (17%)	1,419 (18%)	377 (18%)	1,989 (14%)	741 (13%)	59,434 (35%)
Duration of diabetes mellitus (y)	2 (0-7)	2 (0-7)	2 (2-5)	7 (3-12)	6 (2-12)	7 (3-12)	0 (0-0)
Insulin treatment	49,388 (17%)	16,639 (17%)	606 (8%)	43 (2%)	3,587 (25%)	84 (2%)	16,373 (10%)
Systolic blood pressure (mmHg)	140 (128-150)	140 (128-150)	150 (137-164)	148 (135-163)	139 (127-150)	141 (128-155)	135 (125-145)
Body mass index (kg/m <sup>2</sup> )	29 (26-33)	29 (26-33)	29 (26-32)	30 (27-33)	31 (28-35)	26 (24-29)	32 (28-36)
HbA1c (mmol/mol)	50 (44-59)	50 (44-59)	53 (45-64)	56 (46-69)	63 (55-73)	55 (48-67)	53 (46-65)
Non-HDL (mmol/L)	3.7 (3.0-4.5)	3.7 (3.0-4.5)	3.8 (3.1-4.6)	4.3 (3.6-5.1)	3.9 (3.1-4.6)	3.8 (3.1-4.6)	3.4 (2.7-4.3)
eGFR (mL/min/1.73m <sup>2</sup> ; CKD-EPI)	84 (68-96)	84 (68-96)	72 (61-86)	70 (59-83)	81 (67-94)	79 (65-92)	83 (68-96)
Micro-albuminuria	43,231 (15%)	14,668 (15%)	2,707 (35%)	560 (26%)	2,892 (20%)	1731 (31%)	24,631 (15%)
Macro-albuminuria	20,526 (7%)	6,832 (7%)	201 (3%)	99 (5%)	761 (5%)	276 (5%)	2,318 (1 %)
History of CVD	55,896 (19%)	18,674 (19%)	2,618 (34%)	771 (36%)	4,948 (34%)	1784 (32%)	24,853 (15%)

All data are shown as median (inter quartile range) or frequency (%). NDR: Swedisch National Diabetes Registry. Micro-albuminuria was defined as an albumin/creatinine ratio 3-30 mg/mmol or urine-albumin 20-300mg/l. Macro-albuminuria was defined as an albumin/creatinine ratio >30mg/mmol or urine-albumin >300mg/l.

**Table 2.** Hazard ratios derived from a multi-variable model used in the DIAL model (see footnotes for definitions)

	<b>Cox proportional hazard function A (vascular events)</b>	<b>Cox proportional hazard function B (non-vascular mortality)</b>
	<b>HR (95% CI)</b>	<b>HR (95% CI)</b>
Male sex*	0.91 (0.88 - 0.94)*	0.89 (0.87 - 0.91)*
Current smoking*	1.04 (1.00 - 1.09)*	1.46 (1.43 - 1.50)*
Duration of T2DM (years)	1.02 (1.01 - 1.02)	1.01 (1.01 - 1.01)
Insulin therapy*	1.02 (0.98 - 1.06)*	1.04 (1.01 - 1.07)*
Systolic blood pressure (mmHg) **	1.06 (0.95 - 1.17)**	1.01 (0.93 - 1.10)**
Body mass index (kg/m <sup>2</sup> )**	0.88 (0.81 - 0.97)**	0.89 (0.84 - 0.95)**
HbA1c (mmol/l) **	1.15 (1.05 - 1.26)**	1.00 (1.00 - 1.00)
non-HDL-c (mmol/l) **	1.16 (1.10 - 1.23)**	0.96 (0.92 - 1.00)**
eGFR (ml/min/1.73m <sup>2</sup> )**	0.64 (0.60 - 0.69)**	0.99 (0.99 - 0.99)
Micro-albuminuria	1.18 (1.14 - 1.22)	1.17 (1.14 - 1.20)
Macro-albuminuria	1.23 (1.18 - 1.28)	1.24 (1.20 - 1.28)
History of cardiovascular disease	9.99 (9.63 - 10.36)*	0.25 (0.24 - 0.26)*

\* Age-dependent variables. Hazard ratios are shown for the median age of 65 years.

\*\* Transformed variables. Hazard ratios are shown for the 75 percentile versus the 25 percentile

(Systolic blood pressure: 150 mmHg vs 128 mmHg; Body mass index: 33 kg/m<sup>2</sup> vs 26 kg/m<sup>2</sup>; HbA1c:

59 mmol/l vs 44 mmol/l; eGFR: 96 ml/min vs 68 ml/min; Non-HDLc: 4.5 mmol/l vs 3.0 mmol/l).